Highest-materiality recent filing
PetMed Express sets 2026 Annual Meeting for Aug 11, 2026; shareholder proposal deadline May 31
2026 Annual Meeting will be held virtually on August 11, 2026.
All five director nominees elected: Batushansky, Campbell, LaCamp, Mennen, Solivan; for votes 6.9M-7.3M, against 2.9M-3.5M.
PetMed Express amends 8-K: RSM dismissal effective Dec 19; Baker Tilly appointed
Dismissal of RSM US LLP effective December 19, 2025, after completing interim reviews for June and Sep 2025 quarters.
PetMed Express dismisses RSM as auditor, hires Baker Tilly; cites material weaknesses in controls
Audit Committee dismissed RSM US LLP as independent auditor effective after interim reviews; Baker Tilly US LLP engaged for FY2026.
PetMed Express extends shareholder rights plan to December 2026
Rights plan expiration extended from December 2, 2025 to December 2, 2026.
PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice
Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.
James LaCamp, former Deloitte partner and current CFO of Skydio, appointed to board effective Oct 19, 2025.
PetMed Express FY2025 net sales $227M, net loss $6.3M; Q1/Q2 filings delayed
Net sales of $227.0M for FY2025 below preliminary range of $231.6M-$233.6M due to restatement of promotional sales reimbursements to cost of sales.
PetMed Express to restate FY2024, FY2023; investigation reveals revenue errors, former CEO/CFO out
Net sales overstated by ~$7.0M in FY2024 and ~$9.0M in FY2023 due to vendor payment misclassification; no net income impact.
PetMed Express sets interim CEO salary at $550k, awards restricted shares to CFO
Leslie C.G. Campbell, Interim CEO since Aug 11, 2025, receives $550,000 annual base salary.
PetMed Express receives Nasdaq non-compliance notice; plan due Sept 1, 2025
Nasdaq notified PetMed for late filing of FY2025 10-K and Q1 FY2026 10-Q, violating Listing Rule 5250(c)(1).
CEO Sandra Campos and CFO Robyn D'Elia resigned Aug 11, 2025; severance includes 13-month salary continuation and accelerated RSU vesting.
Director Diana Garvis Purcel resigns from PetMed Board; board size reduced to six
Diana Garvis Purcel resigned effective July 24, 2025 as Board member and Audit Committee Chair.
PetMed Express receives Nasdaq deficiency notice for late FY2025 10-K filing
Received Nasdaq notice on July 2, 2025 for non-compliance with Listing Rule 5250(c)(1) due to delayed annual report.
10-K filing delayed beyond July 1 extension; Audit Committee investigating anonymous whistleblower reports.
PetMed Express prelim Q4 sales $51-53M vs $66.5M; net loss widens to $10M; delays 10-K
Q4 net sales estimated $51.1-53.1M (down ~21% YoY); net loss $9.9-10.4M vs $5.0M prior year.
PetMed Express appoints Peter Batushansky to Board; Dr. Fulgoni to retire at 2025 annual meeting
Peter Batushansky, former CEO of Allivet and current partner at L2 Capital Partners, joins board effective April 9, 2025.
On April 9, 2025, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Peter Batushansky to serve as a director of the Company beginning April 9, 2025.
Dr. Gian Fulgoni, longtime Board member and former Chairman, has communicated his intention to retire from the Board when his term expires at the 2025 annual shareholders’ meeting.
Max materiality 0.85 · Median 0.65 · Most common event leadership